Cardiac valvulopathy associated with pergolide useZADIKOFF, Cindy; ROCHON, Paula; LANG, Anthony et al.Canadian journal of neurological sciences. 2006, Vol 33, Num 1, pp 27-33, issn 0317-1671, 7 p.Article

The long-acting dopamine agonist pergolide mesylate for treatment of hyperprolactinaemiaBERGH, T; NILLIUS, S. J; WIDE, L et al.Acta europaea fertilitatis. 1984, Vol 15, Num 6, pp 421-424, issn 0587-2421Article

The Analysis of Pergolide Residues in Horse Plasma by LC with Fluorescence DetectionDORAN, Gregory; HUGHES, Kristopher; RENDLE, David et al.Journal of AOAC International. 2013, Vol 96, Num 6, pp 1487-1493, issn 1060-3271, 7 p.Article

Valvulopathie réversible et traitement par pergolide = Reversible cardiac valve abnormalities with pergollde treatmentCALOMNE, V; DUPUIS, M. J.-M; MULLER, T et al.Revue neurologique (Paris). 2004, Vol 160, Num 1, pp 81-82, issn 0035-3787, 2 p.Article

Pergolide Associated Cardiac Valvulopathy Based on Ontario Administrative DataZADIKOFF, Cindy; DUONG-HUA, Minh; SYKORA, Kathy et al.Canadian journal of neurological sciences. 2008, Vol 35, Num 2, pp 173-178, issn 0317-1671, 6 p.Article

Diagnosis and management of pergolide-induced fibrosisAGARWAL, Pinky; FAHN, Stanley; FRUCHT, Steven J et al.Movement disorders. 2004, Vol 19, Num 6, pp 699-704, issn 0885-3185, 6 p.Article

Adverse Drug Reactions to Dopamine Agonists: A Comparative Study in the French Pharmacovigilance DatabasePEREZ-LLORET, Santiago; BONDON-GUITTON, Emmanuelle; RASCOL, Olivier et al.Movement disorders. 2010, Vol 25, Num 12, pp 1876-1880, issn 0885-3185, 5 p.Article

Trial of subtherapeutic pergolide in de novo Parkinson's diseaseGROSSET, Katherine; GROSSET, Donald; LEES, Andrew et al.Movement disorders. 2004, Vol 20, Num 3, pp 363-366, issn 0885-3185, 4 p.Article

Long-term study of pergolide in Parkinson's diseaseJANKOVIC, J.Neurology. 1985, Vol 35, Num 3, pp 296-299, issn 0028-3878Article

Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergolineKENANGIL, Giilay; ÖZEKMEKCI, Sibel; KOLDAS, Lale et al.Clinical neurology and neurosurgery. 2007, Vol 109, Num 4, pp 350-353, issn 0303-8467, 4 p.Article

Microbial transformations of pergolide to pergolide sulfoxide and pergolide sulfoneSMITH, R. V; DAVIS, P. J; KERR, K. M et al.Journal of pharmaceutical sciences. 1983, Vol 72, Num 7, pp 733-736, issn 0022-3549Article

Extensive fibromuscular dysplasia in a patient with Parkinson diseaseWANG, Thomas H; MAURO, Matthew; JENNETTE, J. Charles et al.The American journal of the medical sciences. 2004, Vol 327, Num 6, pp 352-355, issn 0002-9629, 4 p.Article

Vascularite cutanée au cours d'un traitement par mésilate de pergolide = Cutaneous vasculitis during pergolide mesilate treatmentSERRATRICE, J; GRANEL, B; DISDIER, P et al.La Revue de médecine interne (Paris). 2002, Vol 23, Num 9, pp 800-801, issn 0248-8663Article

Pergolide binds tightly to dopamine D₂ short receptors and induces receptor sequestrationBARBIER, P; COLELLI, A; MAGGIO, R et al.Journal of neural transmission. 1997, Vol 104, Num 8-9, pp 867-874, issn 0300-9564Article

Efficacy of pergolide in treatment of restless legs syndrome: The PEARLS studyTRENKWALDER, C; HUNDEMER, H.-P; LLEDO, A et al.Neurology. 2004, Vol 62, Num 8, pp 1391-1397, issn 0028-3878, 7 p.Article

Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolideGOETZ, C. G; TANNER, C. M; GLANTZ, R. H et al.Neurology. 1985, Vol 35, Num 5, pp 749-751, issn 0028-3878Article

Meta-analysis of heart valve abnormalities in parkinson's disease patients treated with dopamine agonistsSIMONIS, Gregor; FUHRMANN, Joerg T; STRASSER, Ruth H et al.Movement disorders. 2007, Vol 22, Num 13, pp 1936-1942, issn 0885-3185, 7 p.Article

The in vitro transport of pergolide from surfactant-based elastic vesicles through human skin: a suggested mechanism of actionHONEYWELL-NGUYEN, P. Loan; BOUWSTRA, Joke A.Journal of controlled release. 2003, Vol 86, Num 1, pp 145-156, issn 0168-3659, 12 p.Article

Valvulopathies sous pergolide : revue critique de la littérature et conduite à tenir en pratique = Pergolide associated valvulopathy : critical analysis of the literature and practical recommendationsCORVOL, J.-C; SCHÜPBACH, M; BONNET, A.-M et al.Revue neurologique (Paris). 2005, Vol 161, Num 6-7, pp 637-643, issn 0035-3787, 7 p.Article

PERGOLIDE MESYLATE: NEW THERAPY FOR PERKINSON DISEASETANNER CM; KLAWANS HL.1982; ANN. INTERN. MED.; ISSN 0003-4819; USA; DA. 1982; VOL. 96; NO 4; PP. 522-523; BIBL. 8 REF.Article

Parkinsonism-drig treatment. IIBERG, M. J; EBERT, B; WILLIS, D. K et al.Drug intelligence & clinical pharmacy. 1987, Vol 21, Num 2, pp 167-172, issn 0012-6578Article

Double-blind assessment of potential pergolide-induced cardiotoxicityKURLAN, R; MILLER, C; KNAPP, R et al.Neurology. 1986, Vol 36, Num 7, pp 993-995, issn 0028-3878Article

Pergolide therapy for Parkinson's disease: neurobehavioral changesSTERN, Y; MAYEUX, R; ILSON, J et al.Neurology. 1984, Vol 34, Num 2, pp 201-204, issn 0028-3878Article

Pergolide in Parkinson's diseaseGOETZ, C. G; TANNER, C. M; GLANTZ, R et al.Archives of neurology (Chicago). 1983, Vol 40, Num 13, pp 785-787, issn 0003-9942Article

Intérêt du pergolide dans le traitement de la maladie de Parkinson = Pergolide in Parkinson diseaseBARROCHE, G; GEHIN, P; VESPIGNANI, H et al.Annales médicales de Nancy et de l'Est. 1984, Vol 23, pp 70-73, issn 0221-3796Article